Hudson Institute of Medical Research, Monash University, Clayton, VIC, Australia; Cartherics Pty. Ltd., Clayton, VIC, Australia.
Hudson Institute of Medical Research, Monash University, Clayton, VIC, Australia; Cartherics Pty. Ltd., Clayton, VIC, Australia.
Cell Stem Cell. 2019 Apr 4;24(4):508-510. doi: 10.1016/j.stem.2019.03.003.
In this issue of Cell Stem Cell, Xu et al. (2019) demonstrate that editing iPSCs' major histocompatibility antigens may potentially provide a small set of universally compatible stem cell lines for therapies. However, these modifications may result in patient minor histocompatibility responses and deficiencies in their T cell response repertoire to infection and cancer.
在本期《细胞—干细胞》中，Xu 等人（2019）证明编辑 iPSCs 的主要组织相容性抗原可能为治疗提供一小部分普遍兼容的干细胞系。然而，这些修饰可能导致患者出现次要组织相容性反应，以及其对感染和癌症的 T 细胞反应库缺陷。
